Shearman & Sterling advised the underwriters of Y-mAbs Therapeutics, Inc.’s initial public offering of 6,900,000 shares of common stock (including 900,000 shares purchased by the underwriters pursuant to their option to purchase additional shares) at a public offering price of $16.00 per share, resulting in gross proceeds to the company of approximately $110.4 million. The shares began trading on the Nasdaq Global Select Market under the ticker symbol “YMAB” on September 21, 2018.

BofA Merrill Lynch and Cowen and Company, LLC acted as joint book-running managers for the offering and Canaccord Genuity LLC, and BTIG, LLC acted as co-managers.

Y-mAbs Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company has a broad and advanced product pipeline, including two pivotal-stage product candidates—naxitamab and omburtamab—which target tumors that express GD2 and B7-H3, respectively.

The Team